Abstract: The invention relates to polymorphs of 4′-[2-n-propyl-4-methyl-6-(l-methylbenzimid azol-2-yl)benzimidazol-1-ylmethyl]biphenyl-2-carboxylic acid (INN: telmisartan), particularly polymorphic form B, mixtures of the polymorphs, processes for preparing telmisartan containing form B and the use thereof for preparing a pharmaceutical composition.

Abstract: Tetrahydronaphatalene derivatives, and compositions comprising the compounds. The tetrahydronaphatalene derivates are useful in inhibiting a rise in intracellular calcium mediated by an influx through T-type calcium channels, and are thus useful for treatment of, for example, type 1 and type 2 diabetes and cardiovascular diseases associated with diabetes.

Abstract: Carbonyldiimidazoles of the formulae Ia, Ib, Ic or mixtures thereof where R1 is C1-4-alkyl and R2 is hydrogen or methyl, and tert-butyl esters derived therefrom are described.

Abstract: 1-Guanylpyrazole acid adducts of the formula: wherein R1, R2 and R3 independently of one another are hydrogen, a branched or straight-chain C1-6-alkyl group, a C3-8-cycloalkyl group or a C6-12-aryl group which is unsubstituted or substituted by 1 to 6 alkyl groups; R4 is hydrogen or a straight-chain or branched C1-4-alkyl group; and X is Cl or Br, are prepared by a process which comprises: conducting the reaction of pyrazole or a derivative thereof with cyanamide or a derivative thereof and gaseous hydrogen chloride or hydrogen bromide in an aprotic solvent.

Abstract: Compounds having the formula: are disclosed. M1 and M2 are the same or different and are transition metal atoms or ions; Z2 and Z3, independently, are the atoms necessary to complete a 3-12 membered heterocyclic ring; Z1 is an alkylene or arylene group; Q1 and Q2 are the same or different and are electron withdrawing groups; L1 and L3, taken together, represent —O—CR13—O—; L2 and L4, taken together, represent —O—CR14—O—; and R13 and R14 are the same or different and are selected from the group consisting of alkyl groups and aryl groups or R13 and R14 represent alkylene or arylene groups that are directly or indirectly bonded to one another. Methods for making such compounds are also disclosed, as are intermediates which can be used in their preparation. Also disclosed are methods for carrying out C—H insertion reactions using bis-transition metal catalysts, such as the above compounds.

Abstract: A method for preventing or treating cognitive impairments associated with aging or Alzheimer's disease which comprises treating a patient at risk for having the cognitive impairment with an effective amount of a highly selective butyrylcholinesterase inhibitor.

Abstract: A monomer represented by the following general formula (m-1): wherein R is a group having an alicyclic skeleton, R2s may be the same or different and are individually hydrogen atom, halogen atom or monovalent organic group, X1 is a bivalent organic group containing a heteroatom, j is an integer of 0 to 3, and R1 is a group selected from the following groups, a monovalent organic group having Si (R1-1), and —(X2)k—R4—(X3)m—C(R6)3  (R1-2), wherein X2 and X3 are a bivalent organic group containing a heteroatom, k and m are an integer of 0 to 3, R4 is a bivalent alkyl group, R6s may be the same or different and are individually hydrogen atom, halogen atom or monovalent organic group.

Abstract: Process for preparing optically active &bgr;-amino alcohols represented by a general formula (2): Ra—C*H(OH)—C*H(Rb)—Rc wherein Ra and Rc are each independently hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, Rb is one member selected from among groups represented by the following general formulae; (3) R1CO(R2)N—, and (4) R1CO(R1′CO)N—, and C* is an asymmetric carbon atom, characterized by reacting a racemic &agr;-aminocarbonyl compound represented by the general formula (1): Ra—CO—CH(Rb)—Rc, with hydrogen in the presence of an optically active transition metal compound represented by a general formula (7): MaXY(Px)m(Nx)n wherein Ma represents a metal atom belonging to VIII-group of the periodic law, X and Y represent each independently hydrogen, halogeno, Px represents a phosphine ligand, Nx represents an amine ligand, at least one of Px and Nx is optically active, and m and n each independently represent 0 or an integer of 1 th

Abstract: The present invention provides novel processes for preparing 3(S)-[(5-chloro-1H-indole-2-carbonyl)-amino]-2(R)-hydroxy-4-phenyl-butyric acid. Also provided are novel intermediates used in those processes. Further, the 3(S)-[(5-chloro-1H-indole-2-carbonyl)-amino]-2(R)-hydroxy-4-phenyl-butyric acid prepared by the novel processes can be further reacted to yield known indole 2-carboxamides and derivatives thereof possessing glycogen phosphorylase inhibitory activity, which are useful in the treatment of mammals, especially human beings, having glycogen phosphorylase dependent diseases or conditions.

Abstract: Stable, enzymatically triggered chemiluminescent 1,2-dioxetanes with improved water solubility and storage stability are provided as well as synthetic processes and intermediates used in their preparation. Dioxetanes further substituted with two or more water-solubilizing groups disposed on the dioxetane structure and an additional fluorine atom or lower alkyl group provide superior performance by eliminating the problem of reagent carryover when used in assays performed on capsule chemistry analytical systems. These dioxetanes display substantially improved stability on storage. Compositions comprising these dioxetanes, a non-polymeric cationic surfactant enhancer and optionally a fluorescer, for providing enhanced chemiluminescence are also provided.

Abstract: An object of the present invention is to provide the tocopherol derivatives represented by the following formula (I), and their salts: Wherein, R1, R2 and R3 are H or methyl group, and at least one positions selected from group consisting of the R1, R2 and R3 positions are methyl group; and, A is CH2—CH(CH3)— or CH═C(CH3)— The other object of the present invention is to provide a method for preparing the above tocopherol derivatives. The tocopherol derivatives is prepared by reacting tocopherol with phosphorous oxychloride in an equivalent ratio of 1:1˜1.3, in presence of an organic base, in an organic solvent; reacting the tocopherol dichlorophosphate produced by the above reaction with 3-aminopropanol in presence of an organic base, in an organic solvent; and, hydrolyzing the above products.

Abstract: A process for producing trimellitic anhydride which comprises performing liquid phase oxidation of pseudocumene containing 5% by weight or above of dimethyl bezaldehyde as a raw material for oxidation with air in aliphatic monocarboxylic acid having 1 to 5 carbon atoms as a solvent in the presence of a catalyst comprising both each metal of cobalt, manganese and zirconium and bromine to obtain trimellitic acid and then heat dehydrating trimellitic acid thus obtained or heat treating trimellitic acid thus obtained in the presence of a catalyst comprising 10 ppm or above of Ni thereby producing trimellitic anhydride.

Abstract: Novel spiropyran compounds, particularly with photochromic properties, are disclosed, as well as photochromic compositions and ophthalmic articles containing said compounds. The photochromes have been designed so as to have a high colorability, a high sensitivity to activating radiation breaking the pyran ring, to be entirely or practically free from coloration in a non activated non exposed state, to have an intense coloration following activation and a high coverage of the visible spectrum in combination with at least one other photochrome, and to have high rates of coloration/decoloration. The spiropyrans are easily produced and photochemically stable, and are, e.g., of formula (i), wherein L=(a); (b).

Abstract: The invention provides a method of producing &agr;-tocopherol and &agr;-tocopheryl esters. The method comprises using a biological system to produce farnesol or geranylgeraniol. Then, the farnesol or geranylgernaiol is chemically converted into &agr;-tocopherol or an &agr;-tocopheryl ester.

Abstract: The present invention relates to a new taxane having the structure as in Formula I, and its analogs as depicted in Formula II and Formula III. The invention includes novel semi-synthetic and isolation methods for the preparation of these novel taxanes. Specifically, the present invention relates to the new taxane Canadensol isolated from plants of the Taxus genus in particular, Taxus canadensis. The present invention further relates to the use of these new taxanes as anticancer agents.

Abstract: The object of the invention is to develop baccatin derivatives useful for preparing taxoid compounds such as paclitaxel and a process for the producing the same. The invention provides baccatin derivatives represented by the general formula (I) as well as a process for producing baccatin derivatives represented by the general formula (I) above, which comprises allowing a baccatin represented by the general formula (II) to react with a &bgr;-ketoester in the absence of a catalyst or in the presence of a tin compound or an amine base, preferably under reduced pressure.

Abstract: The present invention provides a method for the direct esterification of stanols and sterols with fatty acids to form stanol/sterol-esters. The method provides a synthetic route that is amenable to large scale production of the esters in high yields. A preferred embodiment employs a food grade process free of organic solvents or mineral acids, does not produce or use non-food grade products and is substantially free of the use of a catalyst.

Abstract: A method for preparing at least one hydroxycholesterol chosen from the group consisting of 25-hydroxycholesterol, 17,25-dihydroxycholesterol and 25,26-dihydroxycholesterol by biological hydroxylation of cholesterol, and the aforementioned dihydroxycholesterols. In the above biological hydroxylation, a microorganism is used which has the abovementioned hydroxylation capacity and which belongs to the genus Amycolata and the genus Sphingomonas.

Abstract: The process of the present invention transforms a steroidal ketone of formula (III) to androst-4-en-17&bgr;-carboxylic acid (IV) by reaction with K2SO5.KHSO4.K2SO4.

Abstract: Novel compositions containing conjugated linoleic acids are efficacious as animal feed additives and human dietary supplements. Linoleic acid is converted to its conjugated forms in which the resulting composition is low in certain unusual isomers compared to conventional conjugated linoleic products.

Abstract: The present invention relates to a process for the isolation of oryzanols from rice bran oil soap stock by (a) saponifying the oil present in soap stock with an alkali followed by neutralisation of the excess alkali, (b) converting the soap stock into anhydrous, porous soap noodles, (c) extracting the soap noodles with an organic solvent, (d) crystallising the crude unsaponifiable matter to remove impurities, (e) subjecting the residue to column chromatography to obtain an oryzanol rich fraction, and (f) recrystallising the oryzanol rich fraction using an organic solvent to obtain pure oryzanol.

Abstract: A method for providing a purified conjugated fatty acid is disclosed. The purified conjugated fatty acid is formed by separating by liquid chromatography a conjugated fatty acid formed by a novel synthesis of reacting an ester of a fatty acid having a four carbon chain such that carbon one bears one hydrogen and one hydroxyl group, carbon two bears two hydrogen atoms, and a double bond is positioned between carbon three and carbon four, with a tosyl chloride or a mesyl chloride to form a tosylate or mesylate of said ester, and reacting the tosylate or mesylate of said ester with diazabicyclo-undecene.

Abstract: A process for preparing boratabenzene derivatives is provided. The process includes the hydrogenation of a compound containing a boranaphthalene functional group to form a boratabenzene-containing compound. Depending on the compound containing a boranaphthalene functional group, the resulting boratabenzene compound may be converted into a catalyst suitable for olefin polymerization. A process for forming a boratabenzene derivative from a halo-dioxaborolane is also provided. In this process, a halo-dioxaborolane is reacted with a piperylide salt for form a pentadienyl dioxaborolane. The pentadienyl-dioxaborolane is reacted with a strong base to form an intermediate boratacyclohexanediene salt. The intermediate boratacyclohexanediene salt is then reacted with a trialkylaluminum compound to form an alkylboratabenzene salt.

Abstract: There are disclosed amphoteric nano-sized metal oxide particles functionalized with silyl esters of a phosphonate and composites thereof with an acrylate-based monomer, including liquid crystal monomers photopolymerizable at ambient temperature. Also disclosed are the method making such functionalized particular by reacting a metal oxide with a silyl ester of a phosphonate in the presence of a non-aqueous solvent and in an inert atmosphere and the method of making the composites wherein the functionalized particles are admixed with an acrylate-based matrix monomer, including liquid crystal monomers photopolymerizable at ambient temperature. Further disclosed is the method of dental repair wherein the composites are applied to a tooth and photopolymerized.

Abstract: A series of emitting materials used for organic EL based on tridentate ligands are characterized as Formula 1, Formula 2 and Formula 3, where: the group O-I-N is a bidentate ligand such as 8-hydroxyquinoline and 2-(o-hydroxyphenyl)-benzoxazole, II, III are unsubstituted or substituted aryl groups. The substituted groups can have 1-8 carbon atoms, halogen, cyano, amino, amido, sulfonyl, carbonyl, aryl, or heteroalkyl groups. The ligand including II and III is a tridentate ligand with three chelate atoms: two oxygen atoms and one nitrogen atom. The central metal atoms can be trivalent or tetravalent atoms such as Al, In, Ga, Tl, and Sn. These materials can be used as emitting materials or electronic transport materials in organic EL devices.

Abstract: Synthesis of N-silylated mono(cyclopentadienyl) ligands and similar indenyl ligands utilizing the novel silanes is described.

Abstract: The present invention is related to diimino compounds of formulae (I) R2—N═C(R1)(R3)nC(R1)═N—R2 and (II) (R1)2C═N—(CR24)m—N═C(R1)2 functionalized with at least one siloxy group. Said diimino compounds are useful for obtaining a solid catalyst component for polymerizing olefins wherein the diimino compound of formulae (I) or (II) is bonded to a porous inorganic support and to a transition metal selected from groups 8, 9 and 10 of the periodic table. This invention also relates to a process for preparing said diimino compounds of formulae (I) or (II), to a process for obtaining said solid catalyst component comprising the combination of the diimino compound and a porous inorganic support. Further, the invention also relates to the use of said solid catalyst in combination with a cocatalyst to polirnenrze olefins.

Abstract: An organosilane preparation, comprising a mixture of one or more organosilanes and one or more fillers, has a fines content of less than 2%.

Abstract: This invention includes a process for producing an alkylsilane, comprising reducing an alkoxysilane in the presence of an alkali metal hydride in the presence of a high boiling solvent. The alkylsilane has a boiling point lower than the boiling point of the solvent, which is typically diglyme. This invention also includes a chloride-free alkylsilane formed from the reduction of an alkoxysilane in the presence of an alkali metal hydride. The alkylsilane produced according to the process of the present invention may be useful in microelectronic applications, such as in the production of chloride-free low dielectric constant materials which may be produced by the chemical vapor deposition of such silanes.

Abstract: In a process for preparing trialkoxysilanes by reaction of silicon metal with an alcohol in an inert solvent in the presence of a copper catalyst, the copper catalyst used is a copper salt whose anion contains at least one nonhydrolyzable fluorine atom, or a mixture thereof with other salts.

Abstract: A continuous method for performing a hydrosilylation reaction comprising effecting a hydrosilylation reaction between a liquid organosilicon compound (A) having in each molecule at least one silicon-bonded hydrogen atom and a liquid organosilicon compound (B) having in each molecule at least one aliphatic unsaturated bond in the presence of a platinum catalyst (C) continuously in a tubular reactor equipped with a stirring and plug-flow maintaining apparatus located within the reactor.

Abstract: Novel and useful optical active 2-aralkyl-3-sulfonyloxy-1-propanol and 2-aralkyl-3-sulfonyloxypropionic acid are provided by using an optical active 2-aralkyl-3-acyloxy-1-propanol as a starting material. Furthermore, an optical active 2-aralkyl-3-thiopropionic acid, which is an important intermediate of enkephalinase inhibitor, is provided. According to the present invention, industrially useful optical active sulfonic acid ester derivatives can be provided.

Abstract: An integrated method is disclosed for removing and recovering a substantially water-soluble solvent and at least one metal from an organic reaction mixture comprising at least about 35% by weight aromatic hydroxy compound, which comprises the steps of: (i) contacting a reaction mixture at least once with aqueous acid, (ii) mixing the organic and aqueous phases in the presence of an oxygen source, (iii) separating the organic and aqueous phases wherein said solvent remains substantially in the organic phase; (iv) recovering metal species from the aqueous phase; and (v) recovering said solvent from the organic phase.

Abstract: aPL analogs that (a) bind specifically to B cells to which an aPL epitope binds and are disclosed. Optimized analogs lack T cell epitope(s) are useful as conjugates for treating aPL antibody-mediated diseases. Conjugates comprising aPL analogs and nonimmunogenic valency platform molecules are provides as are novel nonimmunogenic valency platform molecules and linkers. Methods of preparing and identifying said analogs, methods of treatment using said analogs, methods and compositions for preparing conjugates of said analogs and diagnostic immunoassays for aPL antibodies are disclosed.

Abstract: The invention relates to a process for the preparation of resols by reacting phenolic compounds with aldehydes with catalysis by metal salts whose cation can easily be precipitated as low-solubility salts in industrial processes. In this process, a dispersant is added to the reaction mixture comprising phenolic compound, aldehyde and metal salt before, during or after the condensation reaction, and a complexing agent is admixed after the condensation reaction is complete and after the dispersant has been admixed. The resultant resins are transparent even after neutralization using sulphuric acid.

Abstract: The present invention provides a salicylic acid ester derivative having an impurity content lower than a specific level and expressed by the following formula (1) (in the formula, R1 is methyl group or ethyl group, R2, which may be substituted optionally, is an alkyl group having a carbon number of from 1 to 30, alkoxy group having a carbon number of from 1 to 30, aryl group having a carbon number of from 6 to 30, aryloxy group having a carbon number of from 6 to 30, aralkyl group having a carbon number of from 6 to 30 or aralkyloxy group having a carbon number of from 6 to 30). The salicylic acid ester derivative is effective as a terminal blocking agent or a polymerization. promoting agent for a polycarbonate, and gives a polycarbonate having good color tone and suitable for optical material use.

Abstract: Organic diurethanes and/or polyurethanes are prepared by reacting organic diamines and/or polyamines (a) with urea and/or alkyl cabamates (b) and alcohols (c) in the presence of soluble zirconium compounds, preferably zirconium alkoxides, zirconium acetate or zirconium acetylacetonate, as catalyst (d). They can be used for preparing diisocyanates and/or polyisocyanates by thermal dissociation.

Abstract: The invention provides novel prostaglandin analogs. In particular, the present invention relates to compounds having a structure according to formula (I) wherein R1, R2, R3, R4, R5, R6, W, X, Z, a, b, p and q are defined below. This invention also includes optical isomers, diastereomers and enantiomers of formula (I), and pharmaceutically-acceptable salts, biohydrolyzable amides, esters, and imides thereof. The compounds of the present invention are useful for the treatment of a variety of diseases and conditions, such as bone disorders and glaucoma. Accordingly, the invention further provides pharmaceutical compositions comprising these compounds. The invention still further provides methods of treatment for bone disorders and glaucoma using these compounds or the compositions containing them.

Abstract: Disclosed are compounds which bind &agr;4&bgr;7 integrin. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by &agr;4&bgr;7 integrin. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

Abstract: Diphosphonates or their salts between acids and linear, branch substituted and non-substituted, cyclic, heterocyclic and aromatic amino alcohols are used to treat osteoporosis. Pharmaceutical compositions and therapeutic methods of treating osteoporosis are described.

Abstract: The present invention is a method of producing dry, alkali metal or ammonium carboxylic acid salt particles. In accordance with the invention, a molten carboxylic acid is mixed with a solution of an alkali metal-containing or ammonium-containing alkaline compound and the carboxylic acid and alkaline compound are reacted to form the carboxylic acid salt. Water is then removed from the carboxylic acid salt to produce dry, carboxylic acid salt particles. The feed ratio of the molten carboxylic acid and the alkaline compound is controlled to neutralize the carboxylic acid in the process.

Abstract: A process for recovering cobalt and manganese components from a product stream or a residue stream that resulted from a process which employs a catalyst system containing the cobalt and manganese components for oxidizing pseudocumene to trimellitic acid includes the steps of adding a precipitating agent to the product stream or the residue stream in an effective amount to react with the cobalt and manganese components in the product stream or the residue stream.

Abstract: In a process for the preparation of acrolein by gas-phase partial oxidation under heterogeneous catalysis, a reaction gas starting mixture which contains propene and molecular oxygen in a molar C3H6:O2 ratio of >1 is reacted in reaction zones connected in series, at elevated temperatures, over solid-state catalysts, further molecular oxygen being added to the reaction gas mixture in the course of the partial oxidation.

Abstract: A process for vapor phase catalytic oxidation of methacrolein to produce methacrylic acid at high yield and with stability over a prolonged period is provided. The process is characterized, in the occasion of producing methacrylic acid by vapor phase catalytic oxidation of methacrolein using a fixed bed shell-and-tube reactor, in that (1) the catalyst layer in each reaction tube is divided into at least two layers in the axial direction of the tube to provide plural reaction zones, and (2) each of the reaction zones is filled with the catalyst in such a manner that the amount of the catalytically active component per unit volume of the reaction tube decreases from the gas inlet portion toward the gas outlet portion.

Abstract: The present invention relates to (2S)-enantiomers of 2-aminoindan derivatives of formula I: and a novel process for the preparation of them.

Abstract: The present invention includes a number of novel intermediates such as the (S)-secondary alcohol of formula (VIIIA) X2—CH2—C*H(OH)—CH2—NH—CO—RN  (VIIIA) and processes for production of pharmacologically useful oxazolidinones.

Abstract: In a process for preparing aromatic polyamine mixtures which contain compounds of the formula (I), H2N—A—CH2—B—NH2  (I) where A and B are 1,4-phenylene radicals each of which independently of one another can have 1 to 4 substituents selected from C1-20 alkyls and halogens, a compound of the formula (IV) H—A—NH—CH2—HN—B—H  (IV) and/or a compound of the formula (V) H—A—NH—CH2—B—NH2  (V) where A and B are substituted as above, are reacted at from 20° C. to 200° C.

Abstract: 3-amino-3-arylpropan-1-ol compounds of formula I: R1 and R2 independently denoting C1-6 alkyl, or together denoting a (CH2)2-6 ring optionally substituted by phenyl, R3 denoting C3-6 alkyl, C3-6 cycloalkyl, aryl optionally containing heteroatoms and optionally substituted by R6 to R8, or a substituted C1-3 alkylphenyl of formula XII:  R4 and R5 independently denoting C1-6 alkyl, C3-6 cycloalkyl, phenyl, benzyl, or phenethyl, or together forming a (CH2)3-6 or CH2CH2OCH2CH2 ring, R6 to R8 independently denoting H, F, Cl, Br, CHF2, CF3, OH, OCF3, OR14, NR15R16, SR14, phenyl, SO2CH3, SO2CF3, C1-6 alkyl, CN, COOR14, or CONR15R16, or together forming a OCH2O, OCH2CH2O, CH═CHO, CH═C(CH3)O or (CH2)4 ring, R14 denoting C1-6 alkyl, phenyl, benzyl, or phenethyl, R15 and R16 independently denoting H, C1-6 alkyl, phenyl, benzyl or phenethyl, and A denoting optionally substituted aryl optionally containing heteroatoms, or a diastereomer or enantiomer or pharmaceutica

Abstract: A nitrate salt of a compound selected from the group consisting of: salbutamol having the formula (I)

Abstract: Amide derivatives and methods of administering the compositions to mammals to treat disorders such as obesity that are mediated by NPY and especially those mediated by NPY via the Y5 receptor.